PO.CL12.02 · 临床研究
含或不含化疗药物的等离子体活化培养基对正常及恶性人乳腺细胞活力的影响
Effect of plasma activated media, with and without chemotherapeutics, on viability of normal and malignant human breast cells
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
用于癌症治疗的化疗会给患者带来使人衰弱的副作用。尽管经过数十年的研究,增强药物敏感性并将毒性降至最低仍是一项重大挑战。冷大气压等离子体(CAP)提供了一种新颖的非热策略来弥补这一空缺。CAP可在细胞水平改变生物学过程,从而放大现有化疗药物的疗效。然而,等离子体处理培养基对正常组织的相对影响仍知之甚少,这构成了临床转化的一个关键障碍。因此,本研究的目标是确定单独使用或与化疗药物联合使用的等离子体处理培养基对正常及恶性人乳腺细胞活力的影响。我们使用恶性乳腺细胞系MCF-7和MDA-MB-231以及相应的正常乳腺细胞系MCF-10A进行了一系列实验,以评估等离子体处理培养基与不同化疗药物(紫杉醇、多西他赛、多柔比星、顺铂、卡铂、5-氟尿嘧啶和吉西他滨)联合的效应。培养基在给药前先暴露于介质阻挡放电(DBD)空气等离子体5、10或20分钟。我们的结果表明,乳腺癌细胞系对等离子体处理培养基的反应性有限,而正常细胞则表现出明显的易感性。MCF-7和MDA-MB-231细胞在5分钟等离子体暴露后活力均未显示显著变化,且在大多数药物条件下,仅在10分钟和20分钟暴露时观察到轻度下降。在所测试的化疗药物中,1 μM的多西他赛表现出最为显著的等离子体增强性癌细胞活力下降。相反,MCF-10A细胞对等离子体处理培养基表现出更高的敏感性,在几乎所有治疗组中,其活力损失均持续约为癌细胞的两倍。这些发现提示,在当前的DBD空气等离子体装置下,所产生的氧化负荷对正常乳腺上皮细胞系造成的损害不成比例地更大,而在所测试的恶性乳腺细胞系中并未产生相应有利的细胞毒性效应。未来的研究将评估不同类型的等离子体单独或与化疗药物联合对正常及乳腺癌细胞的影响,并探究其潜在机制。
查看英文原文 English abstract
Chemotherapy used for cancer treatment results in debilitating side effects for patients. Despite decades of research, enhancing drug sensitivity and minimizing toxicity remains a major challenge. Cold atmospheric plasma (CAP) offers a novel, non-thermal strategy to address this gap. CAP can alter biological processes at the cellular levelto amplify the effects of existing chemotherapeutics. However, the comparative impact of plasma-treated media on normal tissues remains poorly understood and represents a critical barrier to clinical translation. Therefore, the goal wasto determine the effect of the plasma-treated media, alone or in combination with chemotherapeutics, on viability of normal and malignant human breast cells. We conducted a series of experiments using malignant breast MCF-7 and MDA-MB-231 cell lines, and the corresponding normal breast MCF-10A cell line to assess the effects of plasma-treated media combined with different chemotherapeutic agents; paclitaxel, docetaxel, doxorubicin, cisplatin, carboplatin, 5-fluorouracil, and gemcitabine. Media were exposed to dielectric barrier discharge (DBD) air plasma for 5, 10, or 20 minutes before drug administration. Our results demonstrated that breast cancer cell lines showed limited responsiveness to plasma-treated media, whereas normal cells were markedly susceptible. Neither MCF-7 nor MDA-MB-231 cells displayed significant changes in viability following 5-minute plasma exposure, and only modest reductions were observed at 10- and 20-minute exposures across most drug conditions. Among the chemotherapeutics tested, docetaxel at 1 μM exhibited the most pronounced plasma-enhanced reduction in cancer cell viability. In contrast, MCF-10A cells demonstrated heightened sensitivity to plasma-treated media, consistently exhibiting approximately twice the loss of viability observed in cancer cells across nearly all treatment groups. These findings suggest that, within the current DBD air-plasma setup, the oxidative burden generated is disproportionately harmful to normal epithelial breast cell lines and does not produce a correspondingly advantageous cytotoxic effect in the malignant breast cell lines tested. Future studies will evaluate the effect of different types of plasma, alone or combined with chemotherapeutics, on both normal and breast cancer cells, and will investigate the underlying mechanisms.
利益披露 Disclosure
J. Doster, None..
L. Sankaran, None..
C. Xu, None..
N. Gonce, None..
V. Thomas, None..
S. Melendrez, None.
K. Vig,
NSF EPSCoR Future Technologies and Enabling Plasma Processes Program (FTPP) ).
V. Rangarari,
NSF EPSCoR Future Technologies and Enabling Plasma Processes Program (FTPP) ).
S. Pondugula,
NSF EPSCoR Future Technologies and Enabling Plasma Processes Program (FTPP) ).
A. Morey,
NSF EPSCoR Future Technologies and Enabling Plasma Processes Program (FTPP) ).